Argenx reports full year 2020 financial results and provides fourth quarter business update

- biologics license application (bla) for iv efgartigimod accepted for review by u.s. food and drug administration (fda) for generalized myasthenia gravis (gmg)

ARGX Ratings Summary

ARGX Quant Ranking